Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer — AVALON

Platinum-resistant Epithelial Ovarian Cancer Clinical Trial

Official title:
Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer.

Status Terminated

Clinical Trial Summary

Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.

Clinical Trial Description

A Simon two-stage statistical design to assess MVP-S in combination with low dose CPA in platinum-resistant epithelial ovarian cancer patients who have received no greater than 4 previous lines of anti-cancer therapy. MVP-S, previously called DPX-Survivac, was recently evaluated in a small Phase 2 single arm study of ovarian cancer patients known as DeCidE1 (NCT02785250). ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Ovarian Epithelial
Ovarian Neoplasms
Platinum-resistant Epithelial Ovarian Cancer

Clinical Trial Details

NCT number	NCT05243524
Study type	Interventional
Source	ImmunoVaccine Technologies, Inc. (IMV Inc.)
Contact
Status	Terminated
Phase	Phase 2
Start date	August 5, 2022
Completion date	August 31, 2023

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03081702` - A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer	Phase 1/Phase 2
	Terminated	`NCT04244552` - A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies	Phase 1